Aegerion Upbeat On Juxtapid Launch, Stares Down PCSK9 Threat
This article was originally published in The Pink Sheet Daily
Aegerion said the U.S. launch of Juxtapid in its initial HoFH population was going according to plan. Management spoke of a few upside surprises, including the high number of prescribing cardiologists and recently released data showing the PCSK9 class may be inadequate in this orphan indication.
You may also be interested in...
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.
Retail health clinics are undergoing an intense period of partnering and business model change. Although the value proposition is rock solid, the real test will be whether clinics can offer complementary services to traditional primary care, and working with provider groups, help achieve the goal of population health management.